drugset / Trial / NCT03239080

Effect of Denosumab in Erosion Healing in RA

NCT03239080

Phase 2 Completed 110 enrolled Chinese University of Hong Kong
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the effects of denosumab on erosion healing and change in physical function in RA patients.

Timeline

Start
2017-06-19
Primary completion
2020-05-24
Completion
2020-05-24

Drugs

EvaluationDrugModalityDoseRoute
Comparator Denosumab Monoclonal antibody 60 mg Subcutaneous

Indications